# A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

> **NCT00665223** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 437 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** ACR16
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00665223
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-24
- **Primary completion:** 2010-06-14
- **Final completion:** 2010-06-14
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665223, "A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00665223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*